Loading company…
Revagenix develops antibiotic treatments for drug-resistant infections.
Revagenix advances antimicrobial programs for infections including cUTI, HABP/VABP, and neonatal sepsis/BSI. Founded in 2019, the company is based in San Mateo, US. It raised venture funding co-led by Tenmile and Novo Holdings in January 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in